140 related articles for article (PubMed ID: 32533314)
1. Randomized controlled trial of landiolol, a short-acting beta-1 adrenergic receptor blocker, illustrating changes in high-molecular weight adiponectin levels after elective percutaneous coronary intervention.
Kiyokuni M; Konishi M; Saigusa Y; Iwata K; Nakayama N; Komura N; Sugano T; Ishigami T; Ishikawa T; Yamanaka T; Tamura K; Kimura K
Heart Vessels; 2020 Nov; 35(11):1510-1517. PubMed ID: 32533314
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of early infusion of landiolol, a very short-acting beta-1 adrenergic receptor blocker, on reperfusion status in acute myocardial infarction.
Kiyokuni M; Konishi M; Sakamaki K; Kawashima C; Narikawa M; Doi H; Iwata K; Tomari S; Nakayama N; Komura N; Mitsuhashi T; Yano H; Sugano T; Ishigami T; Endo T; Ishikawa T; Yamanaka T; Kimura K
Int J Cardiol; 2016 Oct; 221():321-6. PubMed ID: 27404699
[TBL] [Abstract][Full Text] [Related]
3. Intracoronary followed by intravenous administration of the short-acting β-blocker landiolol prevents myocardial injury in the face of elective percutaneous coronary intervention.
Park H; Otani H; Noda T; Sato D; Okazaki T; Ueyama T; Iwasaka J; Yamamoto Y; Iwasaka T
Int J Cardiol; 2013 Aug; 167(4):1547-51. PubMed ID: 22608892
[TBL] [Abstract][Full Text] [Related]
4. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Hanada K; Higuma T; Nishizaki F; Sukekawa T; Yokota T; Yamada M; Saito S; Kushibiki M; Oikawa K; Abe N; Tomita H; Osanai T; Okumura K
Circ J; 2012; 76(2):439-45. PubMed ID: 22156314
[TBL] [Abstract][Full Text] [Related]
5. A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease.
Jinzaki M; Hirano M; Hara K; Suzuki T; Yamashina A; Ikari Y; Iino M; Yamaguchi T; Kuribayashi S
Int J Cardiovasc Imaging; 2013 Jun; 29 Suppl 1(Suppl 1):7-20. PubMed ID: 23784548
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Early Intravenous Landiolol on Myocardial Salvage in Patients with ST-segment Elevation Myocardial Infarction before Primary Percutaneous Coronary Intervention: A Randomized Study.
Miyamoto M; Osawa K; Miyoshi T; Mori A; Yoshikawa M; Oka T; Ichikawa K; Nakamura K; Ito H
Acta Med Okayama; 2021 Jun; 75(3):289-297. PubMed ID: 34176932
[TBL] [Abstract][Full Text] [Related]
7. Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.
Adachi T; Sato A; Baba M; Hiraya D; Hasegawa T; Kuroki K; Hoshi T; Aonuma K
Heart Vessels; 2014 Jul; 29(4):464-9. PubMed ID: 23801459
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of adiponectin and extent of coronary artery disease in patients undergoing elective coronary angiography.
Souza RA; Alves CMR; de Oliveira CSV; Reis AF; Carvalho AC
Braz J Med Biol Res; 2017 Nov; 51(2):e6738. PubMed ID: 29211251
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of landiolol and bisoprolol for prevention of atrial fibrillation after coronary artery bypass grafting: a pilot study.
Sezai A; Nakai T; Hata M; Yoshitake I; Shiono M; Kunimoto S; Hirayama A
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1241-8. PubMed ID: 22858430
[TBL] [Abstract][Full Text] [Related]
10. Landiolol: A Review in Tachyarrhythmias.
Syed YY
Drugs; 2018 Mar; 78(3):377-388. PubMed ID: 29470800
[TBL] [Abstract][Full Text] [Related]
11. Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients.
Yamamoto H; Hamasaki T; Onda K; Nojiri T; Aragaki M; Horie N; Sato N; Hida Y
Trials; 2019 Dec; 20(1):715. PubMed ID: 31829248
[TBL] [Abstract][Full Text] [Related]
12. Acute hemodynamic effects of landiolol, an ultra-short-acting beta-blocker, in patients with acute coronary syndrome: preliminary study.
Hoshi T; Sato A; Nishina H; Kakefuda Y; Wang Z; Noguchi Y; Aonuma K
J Cardiol; 2012 Oct; 60(4):252-6. PubMed ID: 22835733
[TBL] [Abstract][Full Text] [Related]
13. Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.
Miyoshi T; Hirohata A; Usui S; Yamamoto K; Murakami T; Komatsubara I; Kusachi S; Ohe T; Nakamura K; Ito H
Heart Vessels; 2014 Mar; 29(2):178-85. PubMed ID: 23563752
[TBL] [Abstract][Full Text] [Related]
14. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
Kakihana Y; Nishida O; Taniguchi T; Okajima M; Morimatsu H; Ogura H; Yamada Y; Nagano T; Morishima E; Matsuda N;
Lancet Respir Med; 2020 Sep; 8(9):863-872. PubMed ID: 32243865
[TBL] [Abstract][Full Text] [Related]
16. Dose-finding study of landiolol hydrochloride: a short-acting β1-blocker for controlling heart rate during coronary computed-tomography angiography in Japan.
Hirano M; Hara K; Ikari Y; Jinzaki M; Iino M; Hamada C; Kuribayashi S
Adv Ther; 2013 Sep; 30(9):803-18. PubMed ID: 24062147
[TBL] [Abstract][Full Text] [Related]
17. Perioperative use of a beta blocker in coronary artery bypass grafting.
Ogawa S; Okawa Y; Goto Y; Aoki M; Baba H
Asian Cardiovasc Thorac Ann; 2013 Jun; 21(3):265-9. PubMed ID: 24570490
[TBL] [Abstract][Full Text] [Related]
18. Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection.
Nakano T; Shimizu K; Kawashima O; Kamiyoshihara M; Nagashima T; Ibe T; Takeyoshi I
J Clin Pharm Ther; 2012 Aug; 37(4):431-5. PubMed ID: 22059486
[TBL] [Abstract][Full Text] [Related]
19. Gender-Specific Associations between Circulating T-Cadherin and High Molecular Weight-Adiponectin in Patients with Stable Coronary Artery Disease.
Schoenenberger AW; Pfaff D; Dasen B; Frismantiene A; Erne P; Resink TJ; Philippova M
PLoS One; 2015; 10(6):e0131140. PubMed ID: 26083608
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature.
Matsuishi Y; Mathis BJ; Shimojo N; Kawano S; Inoue Y
Vasc Health Risk Manag; 2020; 16():111-123. PubMed ID: 32308404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
